No

IDEX Biometrics Enabling Smart Cards to be Issued by China Construction Bank

Thursday, June 17, 2021 - 7:00am

DCEP is an encrypted, digital version of the renminbi, Chinas national currency, and represents legal tender administered by the Peoples Bank of China, the nations central bank.

Key Points: 
  • DCEP is an encrypted, digital version of the renminbi, Chinas national currency, and represents legal tender administered by the Peoples Bank of China, the nations central bank.
  • A digital renminbi hard wallet resembles a conventional dual-interface smart card, with secure processing, encrypted memory, and near-field communication capabilities in the secure element.
  • The cards stored value is further secured with advanced fingerprint recognition and authentication provided by IDEX Biometrics.
  • The emerging hardware wallet application is an incremental market opportunity beyond the already large market for biometric payment cards.

Registration of Share Capital Increases in IDEX Biometrics 16 June 2021

Wednesday, June 16, 2021 - 11:22am

IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all.

Key Points: 
  • IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all.
  • We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger.
  • We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions.
  • Our total addressable market represents a fast growing multi-billion-unit opportunity.

Presenting strategy to accelerate Equinor’s transition

Tuesday, June 15, 2021 - 5:46am

Today, Equinor ASA (OSE:EQNR, NYSE:EQNR) presents its strategy to accelerate the companys transition while growing cash flow and returns.

Key Points: 
  • Today, Equinor ASA (OSE:EQNR, NYSE:EQNR) presents its strategy to accelerate the companys transition while growing cash flow and returns.
  • Key highlights from the strategy update:
    Accelerating the transition and setting an ambition to reach a 40% reduction in net carbon intensity by 2035, on the way towards net zero by 2050.
  • Our strategy is backed up by clear actions to accelerate our transition while growing cash flow and returns.
  • This is a strategy to create value as a leader in the energy transition, says Anders Opedal, president and CEO of Equinor.

Nordic American Tankers Ltd (NYSE: NAT) – Announces the date for its 2021 Annual General Meeting of Shareholders (AGM)

Thursday, June 10, 2021 - 11:21am

The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business.

Key Points: 
  • The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business.
  • Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.
  • The words believe, anticipate, intend, estimate, forecast, project, plan, potential, will, may, should, expect, pending and similar expressions identify forward-looking statements.
  • We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Election to Equinor's board of directors

Tuesday, June 8, 2021 - 5:45pm

The election of shareholder-elected members to the board of directors enters into effect from 1 July 2021 and is effective until the ordinary election of shareholder-elected members to the board of directors in 2022.

Key Points: 
  • The election of shareholder-elected members to the board of directors enters into effect from 1 July 2021 and is effective until the ordinary election of shareholder-elected members to the board of directors in 2022.
  • Furthermore, the corporate assembly re-elected Hilde Mllerstad, Per Martin Labrthen and Stig Lgreid as employee-elected members of Equinors board of directors.
  • Bjrn Palerud, Hans Einar Haldorsen and Anita Skaga Myking (with this priority) were elected as deputy members for the employee-elected board members.
  • The election of employee-elected members to the board of directors enters into effect from 1 July 2021 and is effective until the ordinary election of employee-elected members to the board of directors in 2023.

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Friday, June 4, 2021 - 2:05pm

These response rates clearly exceed those seen in previous studies for pembrolizumab alone in advanced melanoma of 33-37% ORR and 5-12% CR*.

Key Points: 
  • These response rates clearly exceed those seen in previous studies for pembrolizumab alone in advanced melanoma of 33-37% ORR and 5-12% CR*.
  • The data also shows that the UV1/pembrolizumab combination is safe and well tolerated, with adverse events largely restricted to low grade effects, mainly injection site reactions.
  • Ultimovacs continues to build on the safety and tolerability profile of UV1 with several ongoing Phase I and Phase II clinical studies of UV1 in combination with checkpoint inhibitors.
  • Title: A Phase I Clinical Trial Investigating the Telomerase Vaccine UV1 in Combination with Pembrolizumab in Patients with Advanced Melanoma ; ASCO abstract 2620.

IDEX Biometrics: Employee Share Purchase Plan - 3 June 2021

Friday, June 4, 2021 - 12:49am

The board of directors of IDEX Biometrics ASA has resolved to issue 972,642 ordinary shares at NOK 2.08 per share to employees who participate in the companys Employee Share Purchase Plan (ESPP), which plan was approved by the annual general meeting on 15 May 2020.

Key Points: 
  • The board of directors of IDEX Biometrics ASA has resolved to issue 972,642 ordinary shares at NOK 2.08 per share to employees who participate in the companys Employee Share Purchase Plan (ESPP), which plan was approved by the annual general meeting on 15 May 2020.
  • The participating employees have elected to invest a part of the base salary in ordinary shares in the company.
  • Following the issue, the Company's share capital will be NOK 137,734,306.50 divided into 918,228,710 shares each with a nominal value of NOK 0.15.
  • IDEX discloses transactions by the following primary insiders in IDEX shares ISIN NO0003070609:
    - CEO Vince Graziani acquired 19,984 ordinary shares at NOK 2.08 per share.

Grant of Incentive Subscription Rights in IDEX Biometrics 3 June 2021

Friday, June 4, 2021 - 12:46am

The board of directors of IDEX Biometrics ASA resolved on 3 June 2021 to issue 2,000,000 incentive subscription rights to an officer in the IDEX group.

Key Points: 
  • The board of directors of IDEX Biometrics ASA resolved on 3 June 2021 to issue 2,000,000 incentive subscription rights to an officer in the IDEX group.
  • The grant was made under the company's 2021 incentive subscription rights plan as resolved at the annual general meeting on 12 May 2021.
  • Following the grant there are 62,053,609 subscription rights outstanding in IDEX.
  • Catharina Eklof, Chief Commercial Officer of IDEX Biometrics ASA, received on 3 June 2021 a grant of 2,000,000 incentive subscription rights to shares in IDEX.

Norsk Hydro: Sale completed of Hydro Rolling business area to KPS Capital Partners

Tuesday, June 1, 2021 - 3:30pm

Reference is made to the stock exchange notice of April 29, 2021, stating that Norsk Hydro ASA has received the necessary approvals for the sale of Hydro Rolling to KPS Capital Partners.

Key Points: 
  • Reference is made to the stock exchange notice of April 29, 2021, stating that Norsk Hydro ASA has received the necessary approvals for the sale of Hydro Rolling to KPS Capital Partners.
  • The transaction has today closed.
  • In addition, Hydro has signed a separate agreement to sell its Bonn property, which has been part of the Hydro Rolling, but outside the perimeter of the above transaction, to Cube Real Estate for EUR 27 million.
  • The total enterprise value for Hydro Rolling, including the Bonn property, is EUR 1,407 million.

Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

Tuesday, June 1, 2021 - 1:00pm

The article in The Journal of Translational Medicine outlines the mechanistic rationale for the use of the combination of UV1 with two checkpoint inhibitors, ipilimumab and nivolumab.

Key Points: 
  • The article in The Journal of Translational Medicine outlines the mechanistic rationale for the use of the combination of UV1 with two checkpoint inhibitors, ipilimumab and nivolumab.
  • The NIPU trial is important in understanding the potentially synergistic activities of checkpoint inhibitors and our universal cancer vaccine, UV1, stated Jens Bjrheim, Chief Medical Officer at Ultimovacs.
  • Malignant pleural mesothelioma is a challenging disease to treat even with checkpoint inhibitors that have been effective in other types of cancer.
  • NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.